Mounjaro Sales Surge 502%: Why GLP-1 Drugs Are Taking Over India’s Pharma Market

India’s pharma market is witnessing a major shift as diabetes and weight-management therapies gain rapid traction. PharmaTrac’s August 2026 data shows the overall pharma market grew 10.4%, while the antidiabetic segment rose 15.2% in value. Mounjaro emerged as the country’s top-selling brand, with MAT sales reaching ₹1,256 crore, up 502%. Business Today’s Neetu Chandra Sharma explains the rising demand for GLP-1 drugs and the growing awareness around diabetes and obesity treatments. Abhishek Basumallick, Co-founder & Fund Manager, Shree Rama Managers, remains positive on pharma, citing the potential of GLP-1 therapies and upcoming patent expiries as major opportunities for Indian drugmakers.